Epidermal growth factor enhances short-term potentiation and facilitates induction of long-term potentiation in rat hippocampal slices


     Related Videos
Population Growth: 7 billion estimated on October 31, 2011: Quantitative Aspects of Popula...
LEADERSHIP #6 THE OBAMA FACTOR
LEADERSHIP #4 THE CHURCHILL FACTOR
The X Factor Whats the point?
Jon Stewart on The OReilly Factor

     Related Hubpages

    •  Doc. Url:    Embed Code: 

    • PubMed  status
      (0) (0 Votes)
      Views: (1015)   Date: (15-01-09)   Pages: ()
    • Author:  Abe K  Xie FJ  Saito H.  

    • Abstract:  Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, University of Tokyo, Japan.

         Related Documents

           Related Groups

             Related Science News

               More on Sciencestage

               Answers

               News
          • Dermapen™ for Skin Rejuvenation Exclusively Available in San Antonio at ContourLase Body Institute
            Dermapen™ for Skin Rejuvenation Exclusively Available in San Antonio at ContourLase Body Institute “The Dermapen’s multiple, vibrating needles pierce the skin at 225 to 1000 times per second to enhance rejuvenation results in a manner that is far safer for the client than other methods because there is much less epidermal damage,” said David J. Mozersky, M.D., founder of ContourLase. Because the ...
          • Avila Announces FDA Allowance Of Partner Clovis Oncology's IND Application For CO-1686, An Oral EGFR Mutant-Selective ...
            Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved the first milestone in its Epidermal Growth Factor Receptor (EGFR) Mutant-Selective Inhibitor (EMSI) alliance with Clovis Oncology triggering a $4M milestone payment to Avila.
          • Press Release
            Avila Therapeutics Inc. Posted on:20 Jan 12 Avila Therapeutics™, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved the first milestone in its Epidermal Growth Factor Receptor (EGFR) Mutant-Selective Inhibitor (EMSI) alliance with Clovis Oncology triggering a $4 million milestone payment to Avila.
          • New tumor suppressor gene identified
            A recent study published in Clinical Cancer Research suggests that the protein hVps37A suppresses tumor growth in ovarian cancer. The work, which was funded by the Austrian Science Fund FWF, shows, for the first time, that this protein is significantly reduced in ovarian cancer cells. The scientists also found that this reduction affects a cellular signalling pathway that is associated with the ...
          • Zebrafish ability to 'regenerate' damaged retina 'may be useful for humans'
            Washington, Feb 15 (ANI): Researchers, including one of Indian-origin, have undertaken a new study to understand how zebrafish regenerate damaged retinas after injury, which may help suggest new strategies for one day being able to do the same in humans.
          • This Week in the Journal of Molecular Diagnostics
            Researchers at the University of Utah Health Sciences Center report in the Journal of Molecular Diagnostics on their development of a pyrosequencing-based assay that eliminates interference from pseudogenes . In particular, they examined the phosphatidylinositol 3'-kinase gene, which encodes a kinase involved in epidermal growth factor receptor-related signaling pathway, and is mutated in some ...
          • Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*
            INGELHEIM, Germany--(BUSINESSWIRE)-- FOR NON-US MEDIA ONLY Boehringer Ingelheim announced today the initiation of two phase III clinical trials, LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate ...
          • Study identifies a cause of resistance to colon cancer treatment
            Doctors and researchers of Hospital del Mar and its research institute, the IMIM, have lead a study describing a new pharmacological resistance to cancer. This new mechanism is a mutation in an oncogene called EGFR (epidermal growth factor receptor) causing resistance to treatment using a drug called cetuximab, a monoclonal antibody which specifically attacks the EGFR.
          • The link between TB and a gene mutation that causes lung cancer
            ( International Association for the Study of Lung Cancer ) Research presented in the February 2012 issue of the International Association for the Study of Lung Cancer's Journal of Thoracic Oncology shows a link between TB and mutations in the epidermal growth factor receptor, a type of gene mutation found in non-small cell lung cancer. Researchers concluded that there is a relationship between ...
          • Clovis Oncology Announces FDA Acceptance of Investigational New Drug Application for Oral EGFR Mutant-Selective ...
            Clovis Oncology, Inc. announced today that the U.S. Food and Drug Administration has accepted the Company’s investigational new drug application to begin

               Related on Wikipedia




























           

          Powered free by PHPmotion